Tan, Ai Huey and Lim, Shen-Yang and Chong, Kah Kian and Manap, Mohammad Addin Azhan A. and Hor, Jia Wei and Lim, Jia Lun and Low, Soon Chai and Chong, Chun Wie and Mahadeva, Sanjiv and Lang, Anthony E. (2021) Probiotics for constipation in Parkinson disease :A randomized placebo-controlled study. Neurology, 96 (5). E772-E782. ISSN 0028-3878, DOI https://doi.org/10.1212/WNL.0000000000010998.
Full text not available from this repository.Abstract
To determine whether probiotics are effective for constipation, a common and often difficultto-treat problem, in Parkinson disease (PD). Methods In this double-blind, randomized, placebo-controlled, single-center trial, 280 patients with PD were screened, and 72 eligible patients were block-randomized (1:1) to receive either multistrain probiotics capsules (n = 34) or identical-appearing placebo (n = 38), for 4 weeks. The primary endpoint was the change in the average number of spontaneous bowel movements (SBM) per week during the last 2 weeks of intervention compared with the 2-week preintervention phase, recorded by daily stool diary. Secondary outcome measures included changes in stool consistency, constipation severity score, and quality of life related to constipation. Satisfaction with intervention received was assessed. Change in levels of fecal calprotectin, a marker of intestinal inflammation, was an exploratory outcome. Results SBM increased by 1.0 +/- 1.2 per week after treatment with probiotics and decreased by 0.3 +/- 1.0 per week in the placebo group (mean difference 1.3, 95% confidence interval 0.8-1.8, p < 0.001). Significant improvements were also seen for secondary outcomes after correction for multiple comparisons, including stool consistency (p = 0.009) and quality of life related to constipation (p = 0.001). In the treatment group, 65.6% reported satisfaction with the intervention vs only 21.6% in the placebo group (p < 0.001). One patient (2.9%) in the treatment group withdrew due to a nonserious adverse event. Fecal calprotectin did not change significantly during the study. Conclusions Multistrain probiotics treatment was effective for constipation in PD. Further studies are needed to investigate the long-term efficacy and safety of probiotics in PD, as well as their mechanisms of action. Classification of Evidence This study provides Class I evidence that, for people with PD, multistrain probiotics significantly increased the average number of SBM per week.
| Item Type: | Article |
|---|---|
| Funders: | Ministry of Education, Malaysia Fundamental Research Grant Scheme[FRGS/1/2018/SKK02/UM/02/1] |
| Uncontrolled Keywords: | Controlled-trial;Symptoms;Inflammation;Enterococcus;Microbiome;Prebiotics;Levodopa;Markers;Safety |
| Subjects: | Q Science > QR Microbiology R Medicine R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 13 Sep 2022 05:42 |
| Last Modified: | 13 Sep 2022 05:42 |
| URI: | http://eprints.um.edu.my/id/eprint/34389 |
Actions (login required)
 |
View Item |
